TWiV 1154: Clinical update with Dr. Daniel Griffin

October 4, 2024

In his weekly clinical update, Dr. Griffin discusses the Marburg virus outbreak in Rwanda, the lack of immune durability following pertussis vaccination, recommendations for maternal vaccination and antibody therapy to protect against infant RSV, vaccine security for Mpox, before reviewing the recent statistics on SARS-CoV-2 infection, the WasterwaterScan dashboard, how to put on and take off PPE to avoid contamination, where to find PEMGARDA, a reminder of how and when to use steroids to treat COVID-19, what do when healthcare workers succumb to SARS-CoV-2 infection, the lack of immune durability elicited by mRNA vaccine and the finding of how SARS-CoV-2 infection impacts memory, cognition and reduces grey matter volume.

Click arrow to play
Download TWiV 1154 (24 MB .mp3, 39 min)
Subscribe (free): Apple Podcasts, RSSemail

Become a patron of TWiV!

Links for this episode

Rwanda: Marburg virus disease (WHO)

Passport required?…..Marburg virus commutes to Germany (CIDRAP)

Outbreak of whooping cough/pertussis…..no lifelong immunity following vaccination? (Bloomberg

Protection of infants by maternal antibodies against RSV by either vaccination or nirsevimab (MMWR)

WHO recommendations for RSV: maternal vaccination and antibody shot  (Reuters)

Ziresovir for RSV hospitalized infants (NEJM)

Crawling to effective anti-RSV countermeasures (NEJM)

The $800 million pledge for African mpox response (Reuters)

COVID-19 deaths (CDC)

COVID-19 national and regional trends (CDC)

Waste water scan for 11 pathogens (WastewaterSCan)

COVID-19 variant tracker (CDC)

SARS-CoV-2 genomes galore (Nextstrain)

Doffing your PPE– contact precautions (CID)

mRNA vaccination does not elicit durable immune response (Nature Medicine)

IDSA Guidelines on the Treatment and Management of Patients with COVID-19 (IDSA)

Where to get pemgarda (Pemgarda)

EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD)

CDC Quarantine guidelines (CDC)

NIH COVID-19 treatment guidelines (NIH)

Infectious Disease Society guidelines for treatment and management (ID Society)

Drug interaction checker (University of Liverpool)

Molnupiravir safety and efficacy (JMV)

Convalescent plasma recommendation for immunocompromised (ID Society)

What to do when sick with a respiratory virus (CDC)

When your healthcare provider is infected/exposed with SARS-CoV-2 (CDC)

Managing healthcare staffing shortages (CDC)

Steroids,dexamethasone at the right time (OFID)

Anticoagulation guidelines (hematology.org)

Mechanisms of long COVID and therapeutics (Cell)

Post hospitalization cognitive deficits and grey matter reduction 1 year after COVID-19 (Nature Medicine)

Letters read on TWiV 1154

Dr. Griffin’s COVID treatment summary (pdf)

Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

The post TWiV 1154: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.

Leave a Reply

Your email address will not be published. Required fields are marked *

0 comments on “TWiV 1154: Clinical update with Dr. Daniel Griffin

  1. Komal May 2, 2011

    Can reovirus therapy also be effective against hematologic cancers, like leukemias, or would it only work for solid tumors?

    • I asked Brad Thompson and he replied: Reo works well in the lab
      against leukemias. We are discussing with the NCI a request by them to
      run a REO study on leukemia.

      • B Chin May 11, 2014

        Indeed, it appears that the NCI is going to sponsor a myeloma trial: http://bit.ly/1iEqFbp (Thank god national cancer institutes funding, which is out of the purview of wall street fickleness.)

  2.  A little behind on my listening but this is a fantastic podcast this week.  Hearing the tale of the oncolytic Reo story was great.  And hearing it from someone who has been on both sides of the bench and boardroom is pretty cool.  Keep it up!

  3. vladimir Sep 23, 2011

    Very interesting,  I am currently taking virology with Dr. Isern at FGCU and listening to the TWiV really helps me in the class.

  4. This episode was really interesting.  Any plans to interview some of the proponents of other Oncolytic viruses?  (Maybe someone from Jennerex, for example.)  As a layman, I’m curious to know if the several oncolytic viruses under development complement or compete with each other.

  5. Update: In Dec 2012 Oncolytics has released some preliminary data, with statistical significance (p=.03) for shrinking metastatic tumors at 6-weeks into treatment. The gold-standard effect on overall survival will not be available until the data matures sometime in 2013.